.png)
.png)
CEO Update - 1 July 2024
I will watch the General Election this Thursday with great interest, like the rest of the country, and update you on the new ministers and members of Parliament next week. You can access the policy backgrounds of the main parties and view our webinar on what the campaign has taught us about what our sector should expect from the new parliament and government.
Shaping future leaders in biomanufacturing: insights from MAC LeaP
Over the past nine years, Dr Tony Bradshaw, Managing Director of Biosocius, has collected data from three distinct projects within the biotechnology sector. This effort has yielded unique and valuable insights that can help professionals thrive and build sustainable, fulfilling careers. By analysing behavioural profiles and consulting with industry experts, we can better understand the evolving demands of leadership in bioscience.
Why digital matters for neurodegeneration treatments
Molly Andrews of the UK Dementia Research Institute, Priya Kalia of SciTribe, and Miranda Weston-Smith of BioBeat highlight the urgent need for innovative digital solutions and investments in the accurate diagnosis and effective treatment of neurodegenerative diseases, as emphasised at BioBeat24.
CEO Update - 24 June 2024
In two Newscasts time, we will know the outcome of the UK General Election to be held on Thursday, 4 July. Join our webinar tomorrow at 1 pm where we will discuss what we have learned from the campaigns and manifestoes about potential future policies and people important for our sector after the result.
CEO Update - 17 June 2024
Last week saw the key parties launch their general election manifestoes. This week sees a set piece hosting debate with the core parties talking about their approach to science and innovation at a live hustings at the Royal Society.
Life sciences in the public eye: what can we learn from the manifestoes?
With fewer than twenty days to go and the manifestoes of the main parties now published, the BIA policy team pick apart what each party is pledging for the life science sector.
The evolving life sciences landscape
The life sciences sector in the UK has been the subject of significant attention over recent years. Activity in the sector has been spurred on by a multitude of drivers and its potential has also been frequently highlighted by the UK government.
CEO Update - 10 June 2024
UK General Election and what it might mean for the industry, including Labour's pledges on Brexit and business taxes. Upcoming events including the Cambridge Wide Open Day and the Life Science Leadership Summit. UK tech companies pitching at the London Stock Exchange and Amber Therapeutics securing $100 million in funding.
Women in Biotech Mentoring Programme: Dr Carolina Grandellis
In this interview, Dr Carolina Grandellis, Lead of the Earlham Institute Biofoundry, explores the profound impact of the BIA's Women in Biotech mentoring programme on her professional and personal life.
An urgent call for technical standards and metrics for engineering biology
There are currently very few technical standards and metrics that are specific and appropriate to the field of engineering biology. Across the innovation pipeline, there are opportunities for standards to support faster development and enable accelerated commercialisation of the bioeconomy. In response to this, an effort was undertaken with the objective of identifying key areas where standards and metrics would enable the growth of the global bioeconomy.
CEO Update - 3 June 2024
MSD Merck acquire UK biotech EyeBio for $1.3 billion upfront, ASCO and BIO conference week and the UK General election campaign produces little news for the life science sector.
CEO Update - 28 May 2024
The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.
CEO Update - 20 May 2024
The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.
Spotlight on hearing therapeutics landscape: a clinical perspective
Professor Gerard O’Donoghue shares his perspective as Consultant Neurotologist at Nottingham University Hospitals NHS Trust on why he believes that the development of new treatments and their subsequent clinical adoption are vital for people living with hearing loss.
Deep Biotech companies using engineering biology for good: Epoch Biodesign case study
Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.
Women in Biotech Mentoring Programme: Helen and Kathryn's experience
In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.
Deep Biotech companies using engineering biology for good: Solena Materials case study
Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.
CEO Update - 13 May 2024
It was wonderful to celebrate with RNID, our charity partner of the year, the news that pioneering gene therapy has restored a UK girl's hearing. Read on for updates on MHRA AI-Airlock, AMR action plan and more...
Accelerating biotech innovations and predicting genetic codes: Spotlight on Ingenza
Meet Ian Fotheringham, the Managing Director of Ingenza, a global CRDMO that aims to accelerate clients' journeys from discovery to clinical trials while minimising costs and risks. Their innovative codABLE® algorithm brings predictability to DNA sequence configuration, revolutionizing recombinant production of pharmaceutical and industrial molecules. Join us as we explore Ian's insights and Ingenza's ambitious goals for the future.
Deep Biotech companies using engineering biology for good: Moa Technology case study
A spin-out from Oxford University, Moa Technology is developing next-generation herbicides to tackle a growing crisis in agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.